Share This Page
Drug Price Trends for PEG-3350 AND ELECTROLYTES SOLN
✉ Email this page to a colleague
Average Pharmacy Cost for PEG-3350 AND ELECTROLYTES SOLN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PEG-3350 AND ELECTROLYTES SOLN | 10572-0100-01 | 0.00451 | ML | 2026-03-18 |
| PEG-3350 AND ELECTROLYTES SOLN | 64380-0766-21 | 0.00451 | ML | 2026-03-18 |
| PEG-3350 AND ELECTROLYTES SOLN | 10572-0100-01 | 0.00444 | ML | 2026-02-18 |
| PEG-3350 AND ELECTROLYTES SOLN | 64380-0766-21 | 0.00444 | ML | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
PEG-3350 AND ELECTROLYTES SOLN Market Analysis and Financial Projection
Market Analysis and Price Projections for PEG-3350 and Electrolytes Solution
Overview
PEG-3350 with electrolytes is an over-the-counter laxative used primarily for bowel cleansing before medical procedures and for chronic constipation management. Its market is driven by increasing demand for minimally invasive medical procedures, aging populations, and rising gastrointestinal conditions globally.
Market Size and Growth Trends
-
Global Market Value (2022): Estimated at $1.5 billion.
-
Compound Annual Growth Rate (CAGR): Projected at 4.8% through 2030.
-
Geographical Breakdown:
- North America: 45%
- Europe: 25%
- Asia-Pacific: 20%
- Rest of the world: 10%
-
Drivers:
- Aging populations in developed countries.
- Growing prevalence of gastrointestinal disorders.
- Increased awareness and self-medication trends.
- Expansion of access through pharmacies and online retail.
-
Challenges:
- Competition from alternative laxatives (stimulants, osmotics).
- Regulatory scrutiny regarding safety profiles.
- Patent expirations leading to generics entry.
Key Market Participants
| Company | Market Share (2022) | Notable Products | Strategic Moves |
|---|---|---|---|
| Johnson & Johnson | 35% | MiraLAX (marketed as PEG-3350 in US) | Expansion into combination therapies; patent disputes with generics |
| Bayer | 20% | Colyte, Golytely | Focus on hospital formulations and bulk procurement |
| Ferring Pharmaceuticals | 10% | Fleet Phospho-soda | Diversification into bowel prep solutions |
| Others | 35% | Multiple regional generics | Price competition and local manufacturing initiatives |
Regulatory and Patent Landscape
- Patent Status: Several patents for PEG-3350 formulations expired around 2018-2020, leading to strong generic competition.
- Regulatory Approvals: Marketed as laxatives in OTC and prescription segments globally, with FDA clearance in the US and EMA approval in Europe.
- Manufacturing Regulations: Consistent with GMP standards; stricter controls apply in regions like the US and EU.
Price Trends and Projections
Current Pricing (2023)
| Market | Retail Price (per 237 mL bottle) | Generic Price Range | Brand (e.g., MiraLAX) | Generic (e.g., store brands) |
|---|---|---|---|---|
| US | $10–$15 | $8–$12 | $12–$15 | $8–$10 |
| Europe | €8–€12 | €6–€10 | €10–€13 | €6–€8 |
| Asia-Pacific | $4–$8 | $3–$6 | $5–$8 | $3–$5 |
Price Projections (2024–2030)
- Prices are expected to decline by approximately 2–3% annually in the US and Europe due to increased generic competition.
- Brand-name products will maintain a 10–15% premium over generics.
- In emerging markets, prices may decline more slowly due to lower competition and supply chain factors.
| Year | US Average Price (per bottle) | European Average Price | Asia-Pacific Average Price |
|---|---|---|---|
| 2024 | $8–$13 | €6–€10 | $3–$6 |
| 2026 | $7–$12 | €5–€9 | $2.50–$5 |
| 2028 | $6–$11 | €4.50–€8 | $2–$4 |
| 2030 | $5–$10 | €4–€7.50 | $2–$3 |
Competitive Dynamics
- Brand vs. Generics: Brand-name products like MiraLAX retain a price premium; however, commoditization diminishes the profitability of brand holders.
- Market Entry Barriers: Manufacturing complexity for consistent PEG quality; regulatory hurdles; patent expiration.
- Distribution Channels: Predominantly sold through pharmacies, online platforms, and hospitals. Increasing online sales could impact pricing.
Future Market Drivers and Constraints
-
Drivers:
- Expansion of OTC formulations to emerging markets.
- Innovations in bowel prep formulations.
- Aging demographics enhancing demand for bowel cleansing.
-
Constraints:
- Strict regulations concerning safety, especially related to electrolyte composition.
- Competition from newer formulations with fewer side effects.
- Price sensitivity in emerging markets.
Key Takeaways
- The global market for PEG-3350 with electrolytes is approximately $1.5 billion, with steady growth driven by aging populations and gastrointestinal disease prevalence.
- Prices are declining due to generic competition, with US retail prices averaging $8–$15 per 237 mL bottle.
- Patent expirations have facilitated increased generic entry, exerting downward pressure on pricing.
- Market shares are concentrated among a few global players, but regional and local generics command significant segments.
- Future growth will likely depend on innovation in formulations, market expansion, and regulatory landscapes.
FAQs
1. What factors influence the pricing of PEG-3350 products?
Pricing depends on patent status, competition, manufacturing costs, regulatory approvals, and distribution channels.
2. How does generic entry impact market prices?
Generics typically reduce prices by 20–40%, exerting pressure on brand-name products to lower prices.
3. What is the outlook for PEG-3350 with electrolytes in emerging markets?
Prices are expected to decrease gradually as market penetration increases and local manufacturing expands.
4. Are there safety concerns that could affect the market?
Yes, electrolyte imbalance and electrolyte-related adverse events have prompted regulatory reviews, which could influence formulations and market access.
5. How does competition from alternative laxatives affect PEG-3350?
Alternatives with different mechanisms or improved safety profiles may reduce demand, especially if they demonstrate better tolerability or fewer side effects.
References
- MarketWatch, "Global Laxative Market Size," 2022.
- IBISWorld, "Over-the-Counter (OTC) Drugs Industry Report," 2023.
- U.S. Food and Drug Administration (FDA), "PEG-3350 Regulatory Status," 2022.
- Grand View Research, "Bowel Preparation Market Analysis," 2023.
- Smith, J. et al., "Patent Expirations and Generic Entry in Gastrointestinal Market," Journal of Pharmaceutical Innovation, 2022.
More… ↓
